Sight Sciences Inc
NASDAQ:SGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sight Sciences Inc
Cash Equivalents
Sight Sciences Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sight Sciences Inc
NASDAQ:SGHT
|
Cash Equivalents
$92m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash Equivalents
$2B
|
CAGR 3-Years
51%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash Equivalents
$2.9B
|
CAGR 3-Years
50%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash Equivalents
$4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash Equivalents
$8.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash Equivalents
$2.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
Sight Sciences Inc
Glance View
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. The company is headquartered in Menlo Park, California and currently employs 212 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The company sells both systems through a direct sales model.
See Also
What is Sight Sciences Inc's Cash Equivalents?
Cash Equivalents
92m
USD
Based on the financial report for Dec 31, 2025, Sight Sciences Inc's Cash Equivalents amounts to 92m USD.
What is Sight Sciences Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
-21%
Over the last year, the Cash Equivalents growth was -24%. The average annual Cash Equivalents growth rates for Sight Sciences Inc have been -21% over the past three years .
